Plerintra 25 Mg And 50 Mg 25 mg, 50 mg FC tablet
PDF Leaflet Revision Date: 20 January 2026
Clinical Summary
Quick overview from the medicine insert
Indication
Reduces cardiovascular death risk in heart failure post-myocardial infarction.
Dosage (summary)
Start at 25 mg once daily, titrate to 50 mg once daily as tolerated.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Caution in pregnancy; not recommended during lactation.
Key Drug Interactions
- Potassium-sparing diuretics
- Strong CYP3A4 inhibitors
- ACE inhibitors
- ARBs
Contraindications
- Hypersensitivity to eplerenone
- Serum potassium > 5.0 mmol/L
- Severe renal insufficiency
- Severe hepatic insufficiency
- Combination with ACE inhibitors and ARBs
Common side effects
- Hyperkalaemia
- Dizziness
- Insomnia
- Hypotension
- Diarrhoea
Counselling Points
- Monitor potassium levels
- Take with or without food
- Report dizziness or hypotension
Serious warnings
- Risk of hyperkalaemia
- Monitor renal function
- Caution in elderly
Important Disclaimer
The Plerintra 25 Mg And 50 Mg 25 mg, 50 mg FC tablet professional information leaflet below is the property of Hetero Drugs South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
